<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="177120">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00789581</url>
  </required_header>
  <id_info>
    <org_study_id>SCRI BRE 145</org_study_id>
    <secondary_id>TITAN</secondary_id>
    <nct_id>NCT00789581</nct_id>
  </id_info>
  <brief_title>A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer</brief_title>
  <acronym>TITAN</acronym>
  <official_title>Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SCRI Development Innovations, LLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>SCRI Development Innovations, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, Phase III, open-label, multicenter study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be randomized in a 1:1 ratio to receive one of two different treatment arms.
      Patients in treatment arm 1 will receive AC followed by ixabepilone. Patients in treatment
      arm 2 will receive AC followed by weekly paclitaxel.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Free Survival</measure>
    <time_frame>5.25 years</time_frame>
    <description>Disease-free survival (DFS) defined as the time between randomization and the date of first documented disease recurrence, or death from any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>5.25 years</time_frame>
    <description>Overall survival is defined as the time between randomization to date of death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatment-emergent adverse events as a measure of safety.</measure>
    <time_frame>evry 21 days for duration of treatment</time_frame>
    <description>The number of treatment-related adverse events will be graded using the National Cancer Institute Common Technology Criteria for Adverse Events (NCI CTCAE) v. 3.0.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">614</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Doxorubicin/cyclophosphamide, ixabepilone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 administered for 4 cycles of 21 days each, followed by ixabepilone at 40 mg/m2 given for 4 cycles of 21 days each.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Doxorubicin/cyclophosphamide, paclitaxel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 administered for 4 cycles of 21 days each, followed by paclitaxel at 80 mg/m2 weekly for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Doxorubicin 60 mg/m2</description>
    <arm_group_label>Doxorubicin/cyclophosphamide, ixabepilone</arm_group_label>
    <arm_group_label>Doxorubicin/cyclophosphamide, paclitaxel</arm_group_label>
    <other_name>Adriamycin</other_name>
    <other_name>hydroxydaunorubicin</other_name>
    <other_name>Adriamycin PFS</other_name>
    <other_name>Adriamycin RDF</other_name>
    <other_name>Rubex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide 600 mg/m2</description>
    <arm_group_label>Doxorubicin/cyclophosphamide, ixabepilone</arm_group_label>
    <arm_group_label>Doxorubicin/cyclophosphamide, paclitaxel</arm_group_label>
    <other_name>Endoxan</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Procytox</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Cytophosphane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ixabepilone (Ixempra)</intervention_name>
    <description>Ixabepilone 40 mg/m2</description>
    <arm_group_label>Doxorubicin/cyclophosphamide, ixabepilone</arm_group_label>
    <other_name>Ixempra</other_name>
    <other_name>azaepothilone B</other_name>
    <other_name>BMS-247550</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel (Taxol)</intervention_name>
    <description>Paclitaxel 80 mg/m2</description>
    <arm_group_label>Doxorubicin/cyclophosphamide, paclitaxel</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female patients greater than or equal to18 years of age.

          2. Histologically confirmed invasive unilateral breast cancer (regardless of

             histology).

          3. Early-stage breast cancer, defined as:

               -  Node-positive disease: &gt;0.2-mm metastasis in at least one lymph node
                  (pN1mipN2b)OR

               -  Node-negative, with primary tumor &gt;1.0 cm (T1c-T3).

          4. Definitive loco-regional surgery must have been completed as specified

             below:

               -  Patients must have undergone either breast conservation surgery

                  (i.e., lumpectomy) or total mastectomy.

               -  Surgical margins of the resected section must be histologically free of

             invasive adenocarcinoma and ductal carcinoma in situ.

               -  Surgical margins involved with lobular carcinoma in situ (LCIS) will not

             be considered as a positive margin; therefore, such patients will be eligible for
             this study without additional resection.

               -  Patients must have completed axillary lymph node sampling for the pathologic
                  evaluation of axillary lymph nodes as specified below:

             Sentinel node biopsy and/or either lymph node sampling procedure or axillary
             dissection.

          5. Multicentric and multifocal invasive breast cancer is eligible if loco-regional
             surgery has been completed as described above.

          6. Patients with synchronous bilateral cancers are eligible only if:

               -  All cancers are of triple-negative phenotype, defined as ER-, PR-, HER2-.

               -  Eligibility based on the highest stage grouping.

          7. HER2 negative tumors. HER2 negativity must be confirmed by one of the

             following:

               -  FISH-negative (FISH ratio &lt;2.2), or

               -  IHC 0-1+, or

               -  IHC 2-3+ AND FISH-negative (FISH ratio &lt;2.2).

          8. Estrogen receptor negative (&lt;10% staining by IHC for estrogen receptor).

          9. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.

         10. Patient must be &lt;= 84 days from having completed definitive primary breast surgery
             (either lumpectomy or mastectomy).

         11. MammoSite brachytherapy radiation is acceptable if it is performed

             immediately following surgery and prior to chemotherapy. It is recommended that
             chemotherapy be started no earlier than 2 weeks following the removal of the
             MammoSite balloon catheter.

         12. Adequate hematologic function, defined by:

               -  Absolute neutrophil count (ANC) &gt;1500/mm3

               -  Platelet count &gt;=100,000/mm3

               -  Hemoglobin &gt;9 g/dL

         13. Adequate liver function, defined by:

               -  AST and ALT &lt;=2.5 x the upper limit of normal (ULN)

               -  Total bilirubin &lt;=1.5 x ULN (unless the patient has grade 1 bilirubin

             elevation due to Gilbert's disease or a similar syndrome involving slow

             conjugation of bilirubin).

         14. Adequate renal function, defined by:

               -  Serum creatinine &lt;=1.5 x ULN

         15. Complete staging work-up &lt;=12 weeks prior to initiation of study treatment

             with computed tomography (CT) scans of the chest and abdomen/pelvis (abdomen/pelvis
             preferred; abdomen accepted), and either a positron emission tomography (PET) scan or
             a bone scan.

         16. Adequate cardiac function, defined by a left ventricular ejection fraction

             (LVEF) value of &gt;50% (or normal per institutional guidelines) by MUGA scan or
             echocardiogram (ECHO).

         17. Adequate recovery from recent surgery. At least 1 week must have elapsed from the
             time of a minor surgery (i.e., sentinel node biopsy, port-acath (placement); at least
             3 weeks must have elapsed from the time of a major surgery (i.e., lumpectomy, partial
             or total mastectomy, axillary lymph node dissection, breast reconstruction
             procedure).

         18. Patients with previous history of invasive cancers (including breast cancer)

             are eligible if definitive treatment was completed more than 5 years prior to

             initiating current study treatment, and there is no evidence of recurrent disease.

         19. Women of childbearing potential must have a negative serum or urine pregnancy test
             performed within 7 days prior to start of treatment. If a woman becomes pregnant or
             suspects she is pregnant while participating in this study, she must agree to inform
             her treating physician immediately.

         20. Patient must be accessible for treatment and follow-up.

         21. Women of childbearing potential must agree to use an acceptable method of birth
             control to avoid pregnancy for the duration of study treatment, and for 3 months
             thereafter.

         22. All patients must be able to understand the investigational nature of the

        study and give written informed consent prior to study entry.

        Exclusion Criteria:

          1. Women who are pregnant or breastfeeding.

          2. History of previous diagnosis of invasive breast cancer (unless treated &gt;5 years
             previously with no recurrence). History of previously treated ductal carcinoma in
             situ (DCIS) is acceptable.

          3. Any evidence or suspicion of metastatic disease other than ipsilateral

             axillary lymph nodes.

          4. Any tumor &gt;=T4 (cutaneous invasion, deep adherence, inflammatory breast cancer).

          5. Previous anthracycline chemotherapy.

          6. Concurrent use of CYP3A4 inhibitors from 72 hours prior to initiation of

             study treatment until the end of treatment with ixabepilone.

          7. Previous treatment for this breast cancer (including neoadjuvant

             chemotherapy).

          8. Previous cancer (with the exception of non-melanoma skin cancer or cervical carcinoma
             in situ) in the past 5 years (including invasive contralateral breast cancer).

          9. Peripheral neuropathy of &gt; grade 1 per NCI CTCAE v3.0.

         10. Cardiac disease, including: congestive heart failure (CHF) &gt; Class II per

             New York Heart Association (NYHA) classification; unstable angina (anginal symptoms
             at rest) or new-onset angina (i.e., began within the last 3 months), or myocardial
             infarction within the past 6 months; symptomatic CHF, unstable angina pectoris,
             cardiac arrhythmia, or cardiac ventricular arrhythmias requiring anti-arrhythmic
             therapy.

         11. History of hypersensitivity to CremophorEL (polyoxyethylated castor oil) or

             a drug formulated in CremophorEL such as paclitaxel.

         12. Use of any investigational agent within 30 days of administration of the first dose
             of study drug.

         13. Patients may not receive any other investigational or anti-cancer treatments while
             participating in this study.

         14. Concurrent severe, uncontrolled infection or intercurrent illness including,

             but not limited to, ongoing or active infection, or psychiatric illness/social

             situations that would limit compliance with study requirements.

         15. Mental condition that would prevent patient comprehension of the nature of, and risk
             associated with, the study.

         16. Inability to comply with study and/or follow-up procedures.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Denise A Yardley, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>SCRI Development Innovations, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northeast Alabama Regional Medical Center</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Huntsville</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clearview Cancer Institute</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Southern Alabama</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northeast Arkansas Clinic</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilshire Oncology Medical Group</name>
      <address>
        <city>LaVerne</city>
        <state>California</state>
        <zip>91750</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Hope Cancer and Research Institute</name>
      <address>
        <city>Pomona</city>
        <state>California</state>
        <zip>91767</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Connecticut Hematology Oncology</name>
      <address>
        <city>Norwich</city>
        <state>Connecticut</state>
        <zip>06360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aventura Medical Center</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynn Cancer Institute</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33428</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Care</name>
      <address>
        <city>Davie</city>
        <state>Florida</state>
        <zip>33328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holy Cross Hospital</name>
      <address>
        <city>Ft. Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Regional Cancer Center</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Integrated Community Oncology Network</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Watson Clinic Center for Cancer Care and Research</name>
      <address>
        <city>Lakeland</city>
        <state>Florida</state>
        <zip>33805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Space Coast Medical Associates</name>
      <address>
        <city>Titusville</city>
        <state>Florida</state>
        <zip>32796</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Healthcare</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory/Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Augusta Oncology Associates</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Oncology Associates of Augusta</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Georgia Cancer Specialists</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northeast Georgia Medical Center</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <zip>30501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suburban Hem Onc</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <zip>30045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid-Illinois Hematology &amp; Oncology</name>
      <address>
        <city>Normal</city>
        <state>Illinois</state>
        <zip>61761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology of the North Shore</name>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <zip>60076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Associates of SW Indiana</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology of Indiana</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Medical Group</name>
      <address>
        <city>Terre Haute</city>
        <state>Indiana</state>
        <zip>47802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City Cancer Centers</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cotton O'Neil Cancer Center</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultants in Blood Disorders and Cancer</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baton Rouge General Medical Center</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weinberg Cancer Institute at Franklin Square</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Cancer and Blood Disorders</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fallon Clinic</name>
      <address>
        <city>Worchester</city>
        <state>Massachusetts</state>
        <zip>01608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grand Rapids Clinical Oncology Program</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fairview Medical Oncology Clinic</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55436</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis Cancer Care</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John's Clinic</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Cancer Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Clare's Hospital Oncology and Hematology</name>
      <address>
        <city>Denville</city>
        <state>New Jersey</state>
        <zip>07834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology Associates of Northern NJ</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Oncology and Hematology</name>
      <address>
        <city>Vineland</city>
        <state>New Jersey</state>
        <zip>08360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Mexico Oncology Hematology Consultants</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alamance Regional Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>North Carolina</state>
        <zip>27215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Care</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid Ohio Oncology/Hematology, Inc./ The Mark H. Zangmeister Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology/Oncology Inc</name>
      <address>
        <city>Elyria</city>
        <state>Ohio</state>
        <zip>44035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hickman Cancer Center (Flower Hospital)</name>
      <address>
        <city>Sylvania</city>
        <state>Ohio</state>
        <zip>43560</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bux-Mont Oncology, Fox Chase Cancer Center</name>
      <address>
        <city>Rockledge</city>
        <state>Pennsylvania</state>
        <zip>18960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Carolina Oncology Associates, PA</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lowcountry Hematology Oncology</name>
      <address>
        <city>Mt. Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Cancer Center</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29572</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spartanburg Regional Medical Center</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associates in Hematology Oncology</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chattanooga Oncology Hematology Associates</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Cancer Center</name>
      <address>
        <city>Collierville</city>
        <state>Tennessee</state>
        <zip>38017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology, PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Bend Cancer Center</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78463</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Cancer and Blood Disorders</name>
      <address>
        <city>Ft. Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Oncology Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Texas Oncology and Hematology</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peninsula Cancer Institute</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Institute</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Juan Hospital</name>
      <address>
        <city>San Juan</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <lastchanged_date>June 1, 2016</lastchanged_date>
  <firstreceived_date>November 11, 2008</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Adjuvant</keyword>
  <keyword>Doxorubicin</keyword>
  <keyword>Cyclophosphamide</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>Ixabepilone</keyword>
  <keyword>TITAN</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Epothilones</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
